Neovision Capital
Neovision Capital is an investment firm dedicated to both early and growth-stage investment in Chinese healthcare and TMT sectors.
Business Model:
Revenue: $0
Employees: 0-0
Rankings
Industries / Tags:
Detailed Neovision Capital Information
Geographic Data
Address:
City:
State:
Zip:
Country:
Financial Info
Stage:
Raised Last:
$0
Raised Total:$0
Social
Crunchbase
Metrics
0Website Global Rank
0Website Monthly Traffic
Twitter Followers
Description
Neovision Capital was founded in 2015. Key founders are from Costone Capital, J.P. Morgan and so on. Leveraging its core team’s rich China-operational experiences, international resources, and business acumen, we are actually dedicated to both early and growth-stage investment in healthcare and TMT sector in China. In order to leverage our core assets, we actively contribute expertise in essential services including branding, marketing, channel development, overseas expansion, human resources, and finance.
Contact Phone:
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|---|---|---|
| 5/2019 | Allist Pharmaceuticals | Series A | 173.9M |
| 5/2017 | PANDAINS | Series A | 7.3M |
| 1/2018 | PANDAINS | Series A | 7.7M |
| 6/2022 | Dakang Medical | Series E | 0 |
| 11/2021 | Xgene Pharmaceutical | Series C | 0 |
| 9/2016 | RenRenChe | Series D | 0 |
| 2/2019 | Biostar Technologies | Series B | - |
| 2/2017 | Shanghai Genext Medical Technology | Venture Round | - |
| 2/2018 | Rimag | Series B | 0 |
| 5/2021 | Hualan Pharmaceutical New Materials | Venture Round | - |
| 11/2020 | Hocermed | Series C | 15.1M |
| 5/2021 | MicroApproach Medical | Venture Round | - |
| 4/2022 | Maibang Bio | Series B | 15.7M |
| 3/2019 | Smartee Denti-Technology | Series C | - |
| 2/2017 | Boke | Venture Round | - |
| 1/2022 | RzonTech | Venture Round | - |
| 10/2021 | Chineo | Series B | - |
| 8/2021 | Andisec | Venture Round | - |
| 7/2022 | Sino-Biocan | Series A | - |
| 2/2017 | Oranger | Series B | 10.2M |
| 1/2022 | Nuoyuan Medical | Venture Round | - |
| 12/2021 | Matrixtime Robotics | Series A | 15.7M |
| 8/2021 | Rimag | Series D | 0 |
| 12/2021 | ALVA Systems | Series B | - |
| 4/2017 | ACROBiosystems | Venture Round | - |
| 6/2022 | Xingsai Bio | Seed Round | - |
| 1/2018 | Panda Insurance | Series A | 7.7M |
| 5/2020 | PROPRIUM | Series A | 2.8M |
| 7/2022 | Sino-Biocan | Series A | - |
| 6/2022 | Dakang Medical | Series E | 0 |
| 6/2022 | Xingsai Bio | Seed Round | - |
| 4/2022 | Maibang Bio | Series B | 0 |
| 1/2022 | Nuoyuan Medical | Venture Round | - |
| 1/2022 | RzonTech | Venture Round | - |
| 12/2021 | Matrixtime Robotics | Series A | 0 |
| 12/2021 | ALVA Systems | Series B | - |
| 11/2021 | Xgene Pharmaceutical | Series C | 0 |
| 10/2021 | Chineo | Series B | - |
Startup Industries
Startup Locations
Portfolio Current Status
Portfolio Employee Count
| Name | Price |
|---|
| Name | Size | Announced Date |
|---|
